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Background: Dysregulation of noradrenergic system may play important roles in pathophysiology of
attention-deficit/hyperactivity disorder (ADHD). We examined the relationship between polymorphisms in the
norepinephrine transporter SLC6A2 gene and attentional performance before and after medication in children
with ADHD.
Methods: Fifty-three medication-naïve children with ADHD were genotyped and evaluated using the continuous
performance test (CPT). After 8-weeks of methylphenidate treatment, these children were evaluated by CPT again.
We compared the baseline CPT measures and the post-treatment changes in the CPT measures based on the
G1287A and the A-3081T polymorphisms of SLC6A2.
Results: There was no significant difference in the baseline CPT measures associated with the G1287A or A-3081T
polymorphisms. After medication, however, ADHD subjects with the G/G genotype at the G1287A polymorphism
showed a greater decrease in the mean omission error scores (p = 0.006) than subjects with the G/A or A/A
genotypes, and subjects with the T allele at the A-3081T polymorphism (T/T or A/T) showed a greater decrease in
the mean commission error scores (p = 0.003) than those with the A/A genotypes.
Conclusions: Our results provide evidence for the possible role of the G1287A and A-3081T genotypes of SLC6A2 in
methylphenidate-induced improvement in attentional performance and support the noradrenergic hypothesis for
the pathophysiology of ADHD.
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Attention-deficit hyperactivity disorder (ADHD) is a dis-
order primarily characterised by inattention, impulsivity,
and hyperactivity, with a worldwide prevalence of 5.3% [1].
It has an estimated heritability of approximately 76 per-
cent and is thought to be a complex, polygenic disorder
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reproduction in any medium, provided the orAlthough the aetiology of ADHD is not fully under-
stood, there is evidence that dysregulation of the central
noradrenergic system and the dopaminergic system may
be involved in the pathophysiology of ADHD [3,4]. The
central noradrenergic system is involved in the modula-
tion of attention, working memory, and response inhib-
ition, and it has been suggested that norepinephrine
improves attention by increasing the signal-to-noise
ratio of dopamine-containing neurons, particularly in
the prefrontal cortex [5-7]. The hypothesis that the nor-
adrenergic system is involved in ADHD has been largely
driven by the understanding that medications for the
disorder have drug targets in the catecholamine. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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thylphenidate (MPH), when administered for the treat-
ment of ADHD, acts by inhibiting the norepinephrine
transporter (NET) [8] and the dopamine transporter [9]
and stimulating the noradrenergic alpha2 receptor and
the dopamine D1 receptor [9]. The clinical efficacy of
atomoxetine, a highly selective noradrenergic reuptake
inhibitor, in treating ADHD patients is also consistent
with noradrenergic involvement in the pathophysiology
of ADHD [10,11].
The gene (SLC6A2) that codes for NET, located on
chromosome 16q12.2, is a candidate gene for association
with ADHD [12-14]. A-3081T single nucleotide poly-
morphism (SNP) (rs28386840) in the promoter region
and a G1287A SNP (rs5569) in exon 9 are the two major
polymorphisms investigated in relation to this disorder;
however, the findings are inconsistent. Kim et al. [15]
demonstrated that the T allele at the -3081 polymorph-
ism was associated with ADHD and significantly
decreased promoter function, as compared to the A al-
lele. Joung et al. [16] also found an association between
the presence of the T allele at the -3081 polymorphism
and the occurrence of ADHD in a Korean population.
According to a study by Yang et al. [17], the A/A geno-
type at the G1287A polymorphism was associated with a
poor response to MPH treatment in a Chinese ADHD
population. Although several other studies that followed
did not find a significant association between the A-
3081T or G1287A polymorphisms and ADHD [18-20],
recent studies that examined Korean children with
ADHD found associations between the G/G genotype at
the G1287A polymorphism [21] or the presence of the T
allele at the -3081 polymorphism [22] and an adequate
response to MPH treatment.
Noradrenergic dysfunction related to norepinephrine
transporter-mediated mechanisms may be associated
with cognitive impairments in ADHD. The continuous
performance test (CPT) is one of the most widely used
neuropsychological tests in ADHD. The test assesses
several aspects of attentional performance, including
sustained attention in response to target stimuli and in-
hibitory control in response to non-target stimuli [23]. A
meta-analytic review by Frazier et al. [24] reported that
the CPT measures possess the largest effect size for the
diagnosis of ADHD, and the measures of CPT have re-
cently been proposed as a promising endophenotype for
ADHD [25]. A number of studies, most of which fo-
cused on dopaminergic genes [26], were designed to in-
vestigate the genetic basis of CPT measures. In contrast,
only a few studies have explored the association between
NET genes and CPT measures. Kollins et al. [25]
reported an association between a SLC6A2 SNP
(rs3785155) and response time variability of the CPT in
364 individuals from 152 families with at least one childdiagnosed with ADHD. However, in a study by Cho
et al. [18], there were no significant associations between
genotypes of the G1287A and the A-3081T polymorph-
isms and the CPT measures. More recently, Song et al.
[27] reported that subjects with the homozygous G/G
genotype at the G1287A SNP showed significantly lower
commission errors than subjects without the G/G
genotype.
Considering the associations between NET genes and
the response to MPH treatment or CPT measures previ-
ously reported, we propose that there may be an associ-
ation between the polymorphisms of SLC6A2 and MPH-
induced changes in CPT. To our knowledge, there have
been no studies of the association between SLC6A2 and
MPH-induced changes in CPT. An examination of such
an association would inform the roles of the genetic
polymorphisms of SLC6A2 in the effectiveness of MPH
treatment on core deficits of ADHD and further clarify
the roles of the noradrenergic systems in the genetic
basis of ADHD. Thus, we examined the relationship be-
tween the presence of the G1287A or A-3081T poly-
morphism within the SLC6A2 gene and CPT
measurements before and after 8 weeks of MPH treat-
ment in children with ADHD.
Methods
Subjects
We recruited 53 children with ADHD from a child psy-
chiatric clinic at Seoul National University Hospital in
South Korea. Inclusion criteria were 1) diagnosis with
ADHD according to the DSM-IV criteria, as ascertained
by a child psychiatrist; and 2) age 6–18 years. Exclusion
criteria were 1) any other mental disorders except for
mild oppositional defiant disorder and anxiety disorder
not requiring medication; 2) a past or present history of
neurological illness; 3) an IQ below 70; 4) learning dis-
abilities; 5) any history of substance abuse; and 6) previ-
ous treatment with MPH. All participants were drug-
naïve at the time of study entry. To diagnose ADHD and
any comorbid disorders, we used the Korean Kiddie-
Schedule for Affective Disorders and Schizophrenia-
Present and Lifetime Version (K-SADS-PL) [28]. We
assessed intellectual abilities using the Korean version of
the Wechsler Intelligence scale for Children (KEDI-
WISC) [29].
Procedures
Before medication, parents of participants completed an
attention-deficit hyperactivity disorder rating scale
(ADHD-RS), and participants underwent CPTs. Subjects
received 0.35 ~ 1.77 mg/kg/day MPH (either extended-
release MPH or osmotic release oral system MPH) for
8 weeks. Doses were adjusted depending on each
patient's symptom severity and drug tolerability. The
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maximum dose was 54 mg/day. All subjects took medi-
cations once per day in the morning. After 8 weeks’
MPH treatment, the ADHD subjects underwent the
CPT again. On the day of the CPT, patients were
instructed to take MPH in the morning as usual.
This study was conducted as part of a Health &
Medical Technology R&D program and was approved
by the institutional review board (IRB) for human sub-
jects at the Seoul National University Hospital. Parents/
guardians provided written informed consent, and the
children provided verbal assent to participate in this
study.
Neuropsychological assessments
We used a computerised CPT [23] to measure the
neuropsychological functions of the children with
ADHD. The Korean version of the CPT has been stan-
dardised, and its validity and reliability are well estab-
lished [30]. The four variables recorded were (1)
omission errors (failure to respond to the target), which
are commonly interpreted as a measure of inattention;
(2) commission errors (responding inappropriately to
the non-target), which are commonly interpreted as a
measure of impulsivity; (3) response times for correct
responses to the target, which are interpreted as a meas-
ure of information processing and motor response
speed; and (4) the standard deviation of the response
times for correct responses to the target (response time
variability), which is interpreted as a measure of variabil-
ity or consistency of attention.
Genotyping
Genomic DNA was extracted from whole blood lympho-
cytes using a G-DEXTM II Genomic DNA Extraction
Kit (Intron, Korea). The detection of a single nucleotide
polymorphism was based on an analysis of primer exten-
sion products generated from previously amplified gen-
omic DNA, using a chip-based matrix-assisted laser
desorption/ionisation time-of-flight (MALDI-TOF) mass
spectrometry platform (Sequenom, California, USA).
The SLC6A2 polymorphisms were genotyped as previ-
ously described [15] with slight modifications. In brief,
oligonucleotide primers [5’ - ACG TTG GAT GAG
ACC CTA ATT CCT GCA CCC and 5’ - ACG TTG
GAT GTT CAG GAC CTG GAA GTC ATC for the
G1287A polymorphism] were used to generate polymer-
ase chain reaction (PCR) products. The PCR was per-
formed in a volume of 5 μl containing 1 X PCR buffer
(TAKARA, Japan), 2.5 mM MgCl2, 0.2 mM of each
dNTP, 0.1 U HotStarTaq Polymerase (Qiagen, Germany),
8 pM of each primer, and 4.0 ng of genomic DNA. The
program consisted of denaturation at 95°C for 15 min;
followed by 45 cycles at 95°C for 20 sec, 56°C for 30 sec,and 72°C for 1 min; with a final extension at 72°C for
3 min. Following the PCR, unincorporated dNTP was
removed by the addition of 0.3 U of shrimp alkaline
phosphatase and incubation for 20 min at 37°C, followed
by 5 min at 85°C for enzyme inactivation. The total vol-
ume of each reaction was 9 μl, including hME enzyme
(Thermo Sequenase, GE Healthcare, UK), ACT termin-
ation mix, and 5 μM of extension primer. The primer
extension protocol was started at 94°C for 2 min, fol-
lowed by 55 cycles at 94°C for 5 sec, 52°C for 5 sec, and
72°C for 5 sec. After desalting the reaction products with
SpectroCLEAN (Sequenom), samples were analysed in
the fully automated mode with a MALDI-TOF MassAR-
RAY system (Bruker-Sequenom, California, USA).
Statistical analysis
Allele frequency was determined, and the Hardy-Wein-
berg equilibrium was calculated using a goodness-of-fit
χ2 test.
Due to the small number of individuals with the A/A
genotype for the G1287A polymorphism, the subjects
were dichotomized according to whether or not they
possessed the rare A allele (recessive model). For the A-
3081T polymorphism, which follows a co-dominant in-
heritance pattern, subjects were dichotomized according
to whether or not they possessed the T allele, and this
methodology was based on our previous study that
found an improved response to MPH treatment in
ADHD subjects with the T allele as compared to those
without [22].
Group differences in the clinical variables involving con-
tinuous data were computed using an independent two
sample t-test. Between-group comparisons involving cat-
egorical data were assessed using the χ2 test or Fisher’s
exact test. The association between the evaluated genotypes
and the neuropsychological measurements was investigated
using a one-way analysis of variance (ANOVA) or inde-
pendent two sample t-tests. Between-group differences
according to genotype were assessed based on the percent
change in the CPT measurements [
posttreatment CPT scorebaseline CPT scoreð Þ
baseline CPT score  100], rather than on in-
herent changes, to exclude the influence of baseline CPT
scores on the MPH-induced changes to CPT scores. All
statistical analyses were performed using SPSS (version
12.0; SPSS Inc., Chicago, IL). The significance level was set
at p=0.05/2(SNPs)*4(outcome measures) =0.006.
Results
Of the 53 subjects in this study, 45 (84.9%) were boys
and 8 (15.1%) were girls. According to the DSM-IV cri-
teria, the combined subtype is the most common
(N= 36, 67.9%), followed by the inattentive (N = 14,
26.4%) and hyperactive-impulsive (N = 3, 5.7%) subtypes.
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that the G/G genotype was observed in 31 subjects
(58.5%), the A/G genotype in 19 subjects (35.8%), and
the A/A genotype in 3 subjects (5.7%). The A-3081T
genotype analysis of SLC6A2 revealed that the T/T geno-
type was observed in 12 subjects (18.9%), the A/T geno-
type in 28 subjects (52.8%), and the A/A genotype in 13
subjects (24.5%). The distributions of the genotypes for
the G1287A and the A-3081T polymorphisms were in
agreement with the expected values of the Hardy-Wein-
berg equilibrium (p> 0.99 and p = 0.790, respectively).
Table 1 shows the demographic and clinical character-
istics of the ADHD subjects according to their G1287A
and A-3081T genotypes. When dichotomised according
to whether the subjects have the rare allele or not (G/G
vs. A/G+A/A for G1287A and A/A vs. A/T +T/T for A-
3081T), there were no significant group-differences in
age, gender, intelligence, frequency of subtype, or score
of ADHD-RS.
There were no significant group differences in the
baseline scores on the CPT according to the G1287A
and the A-3081T genotypes (Tables 2 and 3). However,
after 8 weeks’ treatment with MPH, subjects with the G/
G genotype at the G1287A polymorphism showed more
improvement in the mean omission error scoresTable 1 Demographic and clinical characteristics of ADHD subje
G1287A
GG (n = 31) AG+AA (n = 22)
N (%) N (%) X2
Sex 0.06
Male 26 (83.9) 19 (86.4)
Female 5 (16.1) 3 (13.6)
ADHD subtype 4.67
Combined 23 (74.2) 13 (59.1)
Inattentive 8 (25.8) 6 (27.3)
Hyperactive-impulsive 0 (0) 3 (13.6)
Comorbidity
ODD 2 (6.5) 4 (18.2) 1.76
Anxiety disorder 4 (12.9) 3 (13.6) 0.01
Tic disorder 1 (3.2) 1 (4.5) 0.06
Enuresis 2 (6.5) 0 1.48
Mean (SD) Mean (SD) t
Age 9.01 (1.96) 9.12 (1.99) −0.19
IQ 108.74 (14.25) 109.27 (11.54) −0.14
ADHD-RS, total 28.45 (10.60) 28.18 (9.97) 0.09
Inattentive 16.13 (6.38) 15.27 (5.22) 0.52
Hyperactive-impulsive 12.32 (5.49) 12.91 (6.52) −0.35
Mean dose, mg/kg 0.86 (0.33) 0.86 (0.25) −0.01
Abbreviations: ADHD attention-deficit hyperactivity disorder, ADHD-RS ADHD-Rating(p = 0.006) than those with the A/G or A/A genotypes.
Subjects with the G/G genotype showed the greatest de-
crease in omission errors, flowed by those with the A/G
genotype and the A/A genotype (p = 0.023), although the
small number of subjects with the A/A genotype limited
statistical comparisons among the three genotypes
(Table 2, Figure 1A). Subjects with the A/A genotype at
the A-3081T polymorphism showed less improvement
in the mean commission error scores (p = 0.003) than
those with the A/T or T/T genotypes. Subjects with the
T/T genotype showed the greatest decrease in commis-
sion errors, followed by the A/T genotype and A/A
genotype (p = 0.007). Actually, the numbers of commis-
sion errors of subjects with the A/A genotype increased
after treatment, while those of subjects with other geno-
types decreased (Table 3, Figure 1B).
Discussion
We found significant associations between MPH-
induced changes in omission errors of the CPT and the
NET G1287A genotype as well as between MPH-
induced changes in commission errors of the CPT and
the NET A-3081T genotype in Korean children with
ADHD. Patients with the G/G genotype at the G1287A
polymorphism showed a greater improvement incts according to G1287A and A-3081T genotypes of SLC6A2
A-3081T
AA (n= 13) AT+ TT (n= 40)
p-value N (%) N (%) X2 p-value
>0.99 0.39 0.662
12 (92.3) 33 (82.5)
1 (7.7) 7 (17.5)
0.097 3.87 0.145
6 (46.2) 30 (75.0)
6 (46.2) 8 (20.0)
1 (7.7) 2 (5.0)
0.219 0 6 (15.0) 2.20 0.317
>0.99 1 (7.7) 6 (15.0) 0.46 0.667
>0.99 1 (7.7) 1 (2.5) 0.73 0.434
0.505 1 (7.7) 1 (2.5) 0.73 0.434
p-value Mean (SD) Mean (SD) t p-value
0.848 9.26 (2.06) 8.45 (1.47) 1.31 0.198
0.886 109.42 (14.90) 108.83 (12.69) 0.16 0.876
0.926 24.92 (13.28) 29.45 (8.98) −1.40 0.169
0.607 14.31 (6.92) 16.25 (5.53) −1.03 0.306
0.725 10.62 (7.58) 13.20 (5.18) −1.39 0.171
0.996 0.78 (0.31) 0.89 (0.28) −1.10 0.277
Scale.
Table 2 Baseline neuropsychological characteristics and post-treatment changes according to the G1287A genotype of
SLC6A2
GG (=31) GA(n = 19) AA(n = 3) GG (n = 31) GA+AA (n= 22)
Mean (SE) Mean (SE) Mean (SE) p-value Mean (SE) Mean (SE) Difference (95% CI) p-value
Baseline
Omission errors 66.87(4.18) 61.16(4.68) 52.00 (4.62) 0.421 66.87(4.18) 59.91 (4.12) 6.96 (-5.20-19.12) 0.256
Commission errors 54.97 (3.44) 61.74 (6.61) 53.00 (7.55) 0.567 54.97 (3.44) 60.55 (5.75) −5.58 (-18.27-7.12) 0.382
Response time 58.52 (2.98) 54.95 (3.40) 55.67 (2.85) 0.728 58.52 (2.98) 55.05 (2.94) 3.47 (-5.20-12.14) 0.425
Response time variability 66.26 (2.77) 64.95 (4.85) 67.00 (8.02) 0.961 66.26 (2.77) 65.23 (4.27) 1.03 (-8.75-10.82) 0.833
Post-treatment change (%)a
Omission errors −17.03 (3.25) −2.09 (4.96) −0.30 (4.19) 0.023 −17.03 (3.25) −1.85 (4.3) −15.19 (-25.81 to -4.57) 0.006
Commission errors −5.89 (3.74) −3.23 (5.47) −0.8 (1.83) 0.870 −5.89 (3.74) −2.90 (4.72) −2.98 (-14.95-8.99) 0.619
Response time 0.35 (6.16) −13.19 (6.23) −6.33 (7.20) 0.338 0.35 (6.16) −12.26 (5.45) 12.61 (-4.75-29.96) 0.151
Response time variability −6.89 (3.11) −4.39 (2.96) −6.70 (5.27) 0.678 −6.89 (3.11) −4.70 (2.62) −5.09 9-16.93-6.75) 0.392
a posttreatment CPT scorebaseline CPT scoreð Þ
baseline CPT score  100.
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AA genotype, and patients with the T allele as one of the
alleles (A/T or T/T genotypes) at the A-3081T poly-
morphism showed a greater improvement in commis-
sion errors of the CPT than those with the A/A
genotype.
No differences in pre-treatment CPT performance
were associated with the G1287A or the A-3081T geno-
types, consistent with our previous study [18]. However,
our finding is inconsistent with the recent study by Song
et al.[27], which reported that subjects with the G/G
genotype at the G1287A polymorphism showed signifi-
cantly lower commission errors than those without the
G/G genotype (p = 0.026). The alpha level of their study
(p< 0.05) was less conservative than that of our study
using the Bonferroni correction (p< 0.006).
The omission errors are an indicator of deficits in sus-
tained attention in response to target stimuli. Our data
showed that the G1287A polymorphism may affect theTable 3 Baseline neuropsychological characteristics and post-
SLC6A2
AA (n = 13) AT (n= 28) TT (n = 12)
Mean (SD) Mean (SD) Mean (SD) p-va
Baseline
Omission errors 64.69 (7.00) 61.75 (3.63) 68.42 (7.14) 0.67
Commission errors 51.54 (3.79) 54.64 (3.39) 69.67 (10.02) 0.08
Response time 54.15 (4.19) 58.36 (2.47) 57.25 (6.08) 0.72
Response time variability 69.15 (7.74) 64.46 (2.18 75.42 (4.32) 0.72
Post-treatment change (%)a
Omission errors −14.12 (5.7) −8.75 (3.78) −11.67 (6.27) 0.72
Commission errors 10.05 (8.04) −7.12 (2.92) −14.79 (4.52) 0.00
Response time −15.82 (6.81) 1.26 (6.00) −7.38 (10.27) 0.25
Response time variability −13.12 (5.39) −2.45 (2.33) −6.48 (4.42) 0.15
a posttreatment CPT scorebaseline CPT scoreð Þ
baseline CPT score  100.outcome of MPH treatment on sustained attention defi-
cits in ADHD, with the G/G genotype being associated
with the greatest MPH-induced decrease in omission
errors. This result with MPH is consistent with the
results reported by Yang et al. [17], which indicated that
Chinese ADHD subjects with the G allele (G/A or G/G
genotypes) showed more symptom improvement in re-
sponse to MPH than those with the A/A genotype, and
the results of Song et al. [21], which showed that Korean
ADHD subjects with the G/G genotype evinced more
symptom improvement than those with the A allele (G/
A or A/A genotypes). Together, these findings suggest a
possible adventitious effect of the G allele in MPH-
induced improvement of inattention, whether symptom-
atic or neuropsychological, in ADHD.
Despite the possibility of a role of the G1287A poly-
morphism in treatment response, a previous association
study found no evidence of a biased transmission of any
of the alleles of the G1287A polymorphism in a sampletreatment changes according to the A-3081T genotype of
AA (n= 13) AT+ TT (n= 40) Difference (95% CI)
lue Mean (SD) Mean (SD) Difference (95% CI) p-value
7 64.69 (7.00) 63.75 (3.31) 0.94 (-13.16-15.05) 0.894
8 51.54 (3.79) 59.15 (3.91) −7.61 (-22.10-6.88) 0.297
7 54.15 (4.19) 58.02 (2.47) −3.87 (-13.81-6.06) 0.438
7 69.15 (7.74) 64.75 (1.97) 4.40 (-6.74-15.55) 0.431
8 −14.12 (5.7) −9.63 (3.21) −4.49 (-17.54-8.55) 0.493
7 10.05 (8.04) −9.42 (2.49) 19.48 (6.88-32.09) 0.003
9 −15.82 (6.81) −1.33 (5.18) −14.48 (-34.35-5.39) 0.150
0 −13.12 (5.39) −3.66 (2.09) −11.52 (-24.79-1.74) 0.087
Figure 1 Post-treatment change (%) in continuous performance test measurements according to the presence of the (A) G1287A
genotypes and (B) A-3081T genotypes. Only the significant results are displayed.
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a silent mutation that does not encode protein variants
[31], and we cannot assume that G1287A is linked to
alleles that have an effect on NET expression. However,
G1287A is located within 5 kb from SNPs such as
rs3285157, rs998424, and rs11568324, which are known
to be associated with ADHD and in which linkage dis-
equilibrium is very high (D0= 0.96–1.0) [32]. Thus, it is
possible that the association between G1287A poly-
morphism and the MPH-induced changes in omission
errors results from the high linkage disequilibrium with
these SNPs.
The commission errors are an indicator of deficits in
response inhibition, which is considered to be the core
deficit in ADHD [33,34]. Our data showed that the A-
3081T polymorphism may affect the results of MPHtreatment on response inhibition in ADHD, with the T
allele being associated with an MPH-induced decrease in
commission errors. In terms of response to MPH treat-
ment, this result is consistent with a previous Korean
study in which ADHD subjects with the T allele (A/T or
T/T genotype) showed more symptom improvement in
response to MPH than those with the A/A genotype
[22]. Unexpectedly, the numbers of commission errors
for subjects with the A/A genotype increased following
MPH treatment. However, these increases were not sta-
tistically significant (p = 0.360), and this result should be
interpreted with caution due to the small sample size.
In previous studies, the frequency of the T allele at the
A-3081T polymorphism was significantly higher in
ADHD subjects than in controls [15,16], and this allele
significantly decreased promoter function compared
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of SLC6A2 and the consequent decrease in transcrip-
tional activity in ADHD subjects with the T allele at the
-3081 polymorphism, as reported by Kim et al. [15], may
result in low levels of NET [33,34]. Our finding that
MPH induced more improvement in inhibitory control
deficits in subjects with the T allele at the -3081 poly-
morphism than in those without it may be explained by
reduced levels of NET within the brains of subjects with
the T allele at the -3081 polymorphism because the
NET-blocking effect of MPH may be more prominent
when the levels of NET are low. However, catechol-
amine-degrading enzymes like catecholamine-O-methyl-
transferase (COMT) or monoamine oxidase (MAO) may
degrade any catecholamine that is produced by the
NET-blocking effects of MPH. Therefore, the interaction
effects of the NET and COMT/MAO polymorphisms on
the response to MPH treatment should be investigated
in further research. A specific improvement in inhibitory
control by MPH may be explained by the therapeutic
actions of MPH being associated with the preferential
activation of noradrenergic and/or dopaminergic neuro-
transmission within the prefrontal cortex, which is the
brain area known to mediate response inhibition [35-
40]. Further studies using imaging and genetic
approaches will be required to verify the hypothesis that
the preferential action of MPH in the prefrontal region
is associated with differences in improvement in inhibi-
tory control deficits related to the A-3081T genotypes.
Several limitations may have influenced the findings in
this study. First, the sample size of the present study is
relatively small for genotypic analysis, so the results can-
not be applied to the general population and should be
interpreted carefully. Second, although the levels of per-
formance of CPT and the frequencies of the NET poly-
morphisms in this study are similar to those in previous
reports, we did not compare the CPT performances and
NET polymorphisms of ADHD subjects and controls.
Third, our study assessed CPT only after short-term
MPH treatment outcomes. The MPH-induced neuro-
psychological changes produced by 8 weeks of MPH
therapy may not be the same as long-term MPH-related
changes. Forth, MPH was administered with no control
of adherence by investigators. Finally, only three of the
patients had the minor allele of the G1287A polymorph-
ism, and this prevented precise statistical results.
Conclusions
This preliminary study provides evidence for the possible
roles of the G1287A and A-3081T genotypes of SLC6A2
in MPH-induced improvement in attentional perform-
ance and supports the noradrenergic hypothesis of the
pathophysiology of ADHD. Further studies using larger
sample sizes, controls, and long-term MPH treatment inthe study designs should help to elucidate treatment-
related neuropsychological changes related to genetic
polymorphisms.
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